Case Study

Zuellig Pharma (A): A case for transformation

11 pages
December 2020
Reference: IMD-7-2240

Case (A) describes the situation facing John Davison after joining the company in December 2014 as the new CEO. A failing ERP implementation had led to serious operational issues in Singapore (its home base) and the Philippines (its biggest and most profitable market). Affected hospitals and doctors had complained directly to the Zuellig family, who owns the company. The board fired the two Co-CEOs who had been running the company and brought John in to turn it around. The company had lost ground with the ratio of operating profit to Gross Operating Revenue (GOR) dropping from 30% in 2009 to 14% in 2014. Increased competition leading to falling margins had contributed to this, as had a lack of focus on improving productivity. The company’s most important clients, such as GSK, were threatening to take their business elsewhere if Zuellig Pharma did not fix its operational problems. The organization was fragmented, with a very small head office, disparate processes across the country operations, and no central leadership of key functions such as operations and quality assurance. The board had lost confidence in the leadership team which, in turn, felt that the board was interfering too much and not giving them the freedom to address the problems at hand. The company had invested in a number of businesses it saw as complementing its main distribution core, but these were sub-scale and (with one exception) loss-making. The leadership team needed to urgently develop a turnaround plan.

Learning Objective
  • Turnaround management: Balancing short-term operational excellence with long-term strategic transformation; Balancing exploitation versus exploration.
  • Moving relationships from transactional to strategic in order to create a value ecosystem.
  • Transforming corporate culture.
  • Digitalizing the business model
Keywords
Strategy, Leadership, Transformation, COVID-19
Settings
South-Eastern Asia, Singapore
Zuellig Pharma, Healthcare, Pharmaceuticals
2014 – 2020
Type
Field Research
Copyright
© 2020
Available Languages
English
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

Contact

Research Information & Knowledge Hub for additional information on IMD publications

This case study is part of a series
  • Zuellig Pharma (A): A case for transformation
  • Zuellig Pharma (B): Putting transformation to the test
  • Zuellig Pharma (C): Taking the next leap
This case study is part of a series
  • Zuellig Pharma (A): A case for transformation
  • Zuellig Pharma (B): Putting transformation to the test
  • Zuellig Pharma (C): Taking the next leap
Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics
Zuellig Pharma (B): Putting transformation to the test
By Katharina Lange Tawfik Jelassi and Pallivathukkal Cherian Abraham
Case reference: IMD-7-2241 ©2020
Summary
Case (B) is set in January 2020 when CEO John Davison decided to step down as CEO by end of June 2020. It describes the specific actions of Zuellig...
Reference IMD-7-2241
Copyright ©2020
Copyright owner IMD Copyright
Organization Zuellig Pharma
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications